Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Faze Is Newest Swimmer In Pool of Biotechs Targeting Biomolecular Condensates

Significant Cash Injection

Executive Summary

Buoyed by an $81m Series A financing round, Faze Medicines joins Dewpoint Therapeutics and Nereid Therapeutics in the race to develop small-molecule drugs targeting biomolecular condensates, an emerging field of cell biology.

You may also be interested in...



Deal Watch: Deal Volume On The Rise Heading Into J.P. Morgan

Pfizer, Sanofi, Bristol Myers Squibb, Gilead’s Kite, Lilly’s Dermira, Janssen and Biogen among the major companies announcing transactions this week.

‘We’re On The Edge Of Knowledge,’ Says Dewpoint CEO

Biomolecular condensates were first observed over 100 years ago, but their function – and the role they might play in a broad range of diseases – is only now being rigorously explored by drug developers. New technological development is helping scientists recreate condensates in laboratory conditions, providing insight into fundamental cellular processes. Amir Nashat, CEO of Dewpoint Therapeutics, told In Vivo that the company, following a recent $77m series B round, now has the resources to get to proof of concept for drugs targeting biomolecular condensates.

Options, Expertise And Risk Tolerance Needed For Successful Value-Based Contracts

Biohaven Pharmaceuticals developed six different value-based contracting options to support the launch of acute migraine therapy, Nurtec ODT. Despite contract complexity and lingering regulatory risk, payers are aggressively pursuing value-based contracts, leading even small biopharmas to invest in strong health economics capabilities.

Topics

Related Companies

UsernamePublicRestriction

Register

GB140150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel